Meet the woman leading vaccine innovation in Senegal to fight Rift Valley fever and empower Africa’s next generation of ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...

Discover how mRNA-based blood clots offer a promising new treatment for osteoarthritis, potentially surpassing traditional ...

Russia cancer vaccine could receive approval by August allowing treatment to begin the head of the Gamaleya Research ...

Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for ...

Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

The Stargate Initiative, spearheaded by several tech giants, has raised alarm in the most paranoid parts of the MAGA movement ...

For 2025, Lonza expects strong performance in its CDMO business with CER sales growth approaching 20% and CORE EBITDA margin approaching 30%. Excluding Vacaville, which is expected to contribute ...